Dr. Beroukhim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Boston, MA 02115Phone+1 617-632-3779
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2006
- University of California (San Francisco)Residency, Internal Medicine, 2000 - 2003
- University of California San Francisco School of MedicineClass of 2000
Certifications & Licensure
- MA State Medical License 2002 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Publications & Presentations
PubMed
- A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek
Science Translational Medicine. 2025-02-19 - liomaesourceutreachithupport: A program to identify and initiate supportive care interventions for unmet needs among adult lower-grade glioma patients.Rachel Garcia Fox, Ugonma N Chukwueke, Timothy Sannes, Damien Miran, Daniel Chiu
Neuro-Oncology Practice. 2025-02-01 - A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer.Veronica Rendo, Michael Schubert, Nicholas Khuu, Maria F Suarez Peredo Rodriguez, Declan Whyte
Nature Communications. 2025-01-27
Journal Articles
- PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial CarcinomaRameen Beroukhim, William J Gibson, Clinical Cancer Research
- Author Correction: Targeting Wild-Type KRAS-Amplified Gastroesophageal Cancer Through Combined MEK and SHP2 InhibitionDaniel Catenacci, Adam J Bass, Shaunt Fereshetian, Rameen Beroukhim, Nature
- Genetic and Transcriptional Evolution Alters Cancer Cell Line Drug ResponseTodd R Golub, Rameen Beroukhim, Pratiti Bandopadhayay, Nature
- Join now to see all
Press Mentions
- EMBARGOED: Study Reveals Activity of Navtemadlin in Glioblastoma, Points to Possible Treatment ImprovementsFebruary 19th, 2025
- Everything ChangesMay 27th, 2020
- Study Eyes Partially Lost Essential Genes as Possible Targets in CancerMay 25th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: